31
May
StemCells, Inc. Announces Termination of Phase II Pathway Study Following Review of Data
NEWARK, Calif., May 31, 2016 (GLOBE NEWSWIRE) — StemCells, Inc. (NASDAQ: STEM) (the “Company”) today announced its decision to terminate the Company’s Phase II Pathway Study in spinal cord injury following an in-depth review of data from the study and after obtaining the concurrence of the study’s Interim Analysis Data Monitoring Committee (the “IA-DMC”).